ATE525083T1 - Pharmazeutische zusammensetzung umfassend eine insulinotrope glp-1(7-37) analoge, asp(b28)- insulin, und eine oberflächenaktive verbindung - Google Patents

Pharmazeutische zusammensetzung umfassend eine insulinotrope glp-1(7-37) analoge, asp(b28)- insulin, und eine oberflächenaktive verbindung

Info

Publication number: ATE525083T1
Authority: AT; Austria
Prior art keywords: pharmaceutical composition; asp; insulin; analog; active compound
Prior art date: 2003-11-13

Application number

AT04797450T

Other languages

English (en)

Inventor

Liselotte Bjerre Knudsen

Kristian Tage Hansen

Dorthe Kot Engelund

Svend Ludvigsen

Lars Hansen

Claude Bonde

Ejvind Jensen

Tine Elisabeth Gottschalk Boving

Morten Schlein

Original Assignee

Novo Nordisk As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-11-13

Filing date

2004-11-12

Publication date

2011-10-15

2004-11-12 Application filed by Novo Nordisk As filed Critical Novo Nordisk As

2011-10-15 Application granted granted Critical

2011-10-15 Publication of ATE525083T1 publication Critical patent/ATE525083T1/de

Links

108090001061 Insulin Proteins 0.000 title abstract 2
230000002473 insulinotropic effect Effects 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 2
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title 1
102000004877 Insulin Human genes 0.000 title 1
229940125396 insulin Drugs 0.000 title 1
239000004094 surface-active agent Substances 0.000 title 1
235000012054 meals Nutrition 0.000 abstract 1
238000007911 parenteral administration Methods 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Diabetes (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Endocrinology (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Chemical & Material Sciences (AREA)
Hematology (AREA)
Obesity (AREA)
Chemical Kinetics & Catalysis (AREA)
Toxicology (AREA)
Child & Adolescent Psychology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Emergency Medicine (AREA)
Immunology (AREA)
Epidemiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)

AT04797450T 2003-11-13 2004-11-12 Pharmazeutische zusammensetzung umfassend eine insulinotrope glp-1(7-37) analoge, asp(b28)- insulin, und eine oberflächenaktive verbindung ATE525083T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DKPA200301689		2003-11-13
PCT/DK2004/000788 WO2005046716A1 (en)	2003-11-13	2004-11-12	Soluble pharmaceutical compositions for parenteral administration comprising a glp-1 peptide and a insulin peptide of short time action for treatment of diabetes and bulimia

Publications (1)

Publication Number	Publication Date
ATE525083T1 true ATE525083T1 (de)	2011-10-15

Family

ID=34585770

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04797450T ATE525083T1 (de)	2003-11-13	2004-11-12	Pharmazeutische zusammensetzung umfassend eine insulinotrope glp-1(7-37) analoge, asp(b28)- insulin, und eine oberflächenaktive verbindung

Country Status (5)

Country	Link
EP (1)	EP1684793B1 (de)
JP (1)	JP4800959B2 (de)
AT (1)	ATE525083T1 (de)
ES (1)	ES2373660T3 (de)
WO (1)	WO2005046716A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2298378T3 (es)	2001-06-28	2008-05-16	Novo Nordisk A/S	Formulacion estable de glp-1 modificado.
US7530968B2 (en)	2003-04-23	2009-05-12	Valeritas, Inc.	Hydraulically actuated pump for long duration medicament administration
KR101308912B1 (ko)	2003-06-03	2013-09-23	노보 노르디스크 에이/에스	안정화된 약학적 펩티드 조성물
EP1633391B1 (de)	2003-06-03	2011-10-19	Novo Nordisk A/S	Stabilisierte pharmazeutische peptid zusammensetzungen
KR101243648B1 (ko)	2003-11-20	2013-03-14	노보 노르디스크 에이/에스	제조 및 주사 장치용에 최적인 프로필렌 글리콜 함유펩티드 제제
WO2005056036A2 (en) *	2003-12-09	2005-06-23	Novo Nordisk A/S	Regulation of food preference using glp-1 agonists
US9089636B2 (en)	2004-07-02	2015-07-28	Valeritas, Inc.	Methods and devices for delivering GLP-1 and uses thereof
JP4965446B2 (ja)	2004-08-31	2012-07-04	ノヴォノルディスクアー／エス	ペプチド、ポリペプチド及びタンパク質の安定化のためのトリス（ヒドロキシメチル）アミノメタンの使用
ES2575984T3 (es) *	2004-11-12	2016-07-04	Novo Nordisk A/S	Formulaciones estables de péptidos que contienen un análogo de GLP-1 acilado y una insulina basal
RU2413530C9 (ru) *	2004-11-12	2021-05-18	Ново Нордиск А/С	Стабильные препараты инсулинотропных пептидов
CN103239773B (zh)	2006-03-30	2015-08-26	瓦莱里塔斯公司	多筒式流体递送器械
US20090318353A1 (en) *	2006-08-25	2009-12-24	Novo Nordisk A/S	Acylated Exendin-4 Compounds
CN101861333A (zh)	2007-11-16	2010-10-13	诺沃-诺迪斯克有限公司	包含glp-1肽或毒蜥外泌肽-4和基础胰岛素肽的药物组合物
JP2011506442A (ja) *	2007-12-11	2011-03-03	コンジュケムバイオテクノロジーズインコーポレイテッド	インスリン分泌性ペプチド結合体の製剤
RU2524423C2 (ru)	2008-01-09	2014-07-27	Санофи-Авентис Дойчланд Гмбх	Новые производные инсулина с чрезвычайно замедленным профилем время/действие
PT3228320T (pt)	2008-10-17	2020-03-26	Sanofi Aventis Deutschland	Combinação de uma insulina e de um agonista do glp-1
PH12011502708B1 (en)	2009-07-06	2017-11-10	Sanofi Aventis Deutschland	Insulin preparations containing methionine
SG10201500871TA (en)	2009-11-13	2015-04-29	Sanofi Aventis Deutschland	Pharmaceutical composition comprising a glp-1 agonist and methionine
JP5832439B2 (ja)	2009-11-13	2015-12-16	サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	Ｇｌｐ−１アゴニスト、インスリン及びメチオニンを含む薬学的組成物
BR112012016853A2 (pt) *	2010-01-12	2017-10-17	Novo Nordisk As	"composições farmacêuticas para administração oral de peptídeos de insulina".
CN103179978A (zh)	2010-08-30	2013-06-26	赛诺菲-安万特德国有限公司	Ave0010用于制造供治疗2型糖尿病用的药物的用途
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
JP6367115B2 (ja)	2011-08-29	2018-08-01	サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	２型糖尿病患者の血糖コントロールに使用する組合せ医薬
TWI559929B (en)	2011-09-01	2016-12-01	Sanofi Aventis Deutschland	Pharmaceutical composition for use in the treatment of a neurodegenerative disease
AR092862A1 (es) *	2012-07-25	2015-05-06	Hanmi Pharm Ind Co Ltd	Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HUE035803T2 (en)	2012-12-21	2018-05-28	Sanofi Sa	Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
TWI780236B (zh)	2013-02-04	2022-10-11	法商賽諾菲公司	胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
EP3080154B1 (de)	2013-12-13	2018-02-07	Sanofi	Duale glp-1/gip-rezeptoragonisten
WO2015086728A1 (en)	2013-12-13	2015-06-18	Sanofi	Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201609797A (zh)	2013-12-13	2016-03-16	賽諾菲公司	雙重ｇｌｐ－１／升糖素受體促效劑
WO2015086730A1 (en)	2013-12-13	2015-06-18	Sanofi	Non-acylated exendin-4 peptide analogues
CA2932873A1 (en)	2014-01-09	2015-07-16	Sanofi	Stabilized pharmaceutical formulations of insulin aspart
KR20160104726A (ko)	2014-01-09	2016-09-05	사노피	인슐린 유사체 및/또는 인슐린 유도체의 안정화된 무글리세롤 약제학적 제형
JP6641280B2 (ja)	2014-01-09	2020-02-05	サノフイＳａｎｏｆｉ	インスリンアナログおよび／またはインスリン誘導体の安定化された医薬製剤
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
CN107206058A (zh)	2014-12-12	2017-09-26	赛诺菲-安万特德国有限公司	甘精胰岛素/利西拉来固定比率配制剂
AR102869A1 (es) *	2014-12-16	2017-03-29	Lilly Co Eli	Composiciones de insulina de rápida acción
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
GB201607918D0 (en)	2016-05-06	2016-06-22	Arecor Ltd	Novel formulations
BR112020002804A2 (pt)	2017-08-24	2020-07-28	Novo Nordisk A/S	composição farmacêutica líquida, e, kit
SG11202111312UA (en)	2019-06-14	2021-12-30	Zealand Pharma As	Pharmaceutical parenteral composition of dual glp1/2 agonist
IL294521A (en)	2020-02-18	2022-09-01	Novo Nordisk As	glp-1 compounds and their uses
TWI921427B (zh) *	2020-12-16	2026-04-11	丹麥商西蘭製藥公司	Glp-1/glp-2雙重促效劑之醫藥組合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PH25772A (en) *	1985-08-30	1991-10-18	Novo Industri As	Insulin analogues, process for their preparation
IL93282A (en) *	1989-02-09	1995-08-31	Lilly Co Eli	Insulin analogues
US5514646A (en) *	1989-02-09	1996-05-07	Chance; Ronald E.	Insulin analogs modified at position 29 of the B chain
EP0929576A1 (de) *	1996-08-30	1999-07-21	Novo Nordisk A/S	Glp-2 derivate
US6458924B2 (en) *	1996-08-30	2002-10-01	Novo Nordisk A/S	Derivatives of GLP-1 analogs
DE122009000079I2 (de) *	1996-08-30	2011-06-16	Novo Nordisk As Novo Alle	Glp-1 derivate
JP4798814B2 (ja) *	1997-01-07	2011-10-19	アミリン・ファーマシューティカルズ，インコーポレイテッド	食物摂取低減用のエキセンジンおよびそのアゴニストの使用
EP1196189A2 (de) *	1999-06-25	2002-04-17	Medtronic MiniMed, Inc.	Unterschiedliche wirkstoffe für diabetestherapie
EP1076066A1 (de) *	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptide zur Senkung des Blutglukosespiegels
AU2353701A (en) *	2000-01-11	2001-07-24	Novo Nordisk A/S	Transepithelial delivery of glp-1 derivatives
WO2003020201A2 (en) *	2001-08-28	2003-03-13	Eli Lilly And Company	Pre-mixes of glp-1 and basal insulin

2004
- 2004-11-12 JP JP2006538658A patent/JP4800959B2/ja not_active Expired - Fee Related
- 2004-11-12 EP EP04797450A patent/EP1684793B1/de not_active Expired - Lifetime
- 2004-11-12 ES ES04797450T patent/ES2373660T3/es not_active Expired - Lifetime
- 2004-11-12 WO PCT/DK2004/000788 patent/WO2005046716A1/en not_active Ceased
- 2004-11-12 AT AT04797450T patent/ATE525083T1/de not_active IP Right Cessation

Also Published As

Publication number	Publication date
JP2007510675A (ja)	2007-04-26
EP1684793B1 (de)	2011-09-21
EP1684793A1 (de)	2006-08-02
WO2005046716A1 (en)	2005-05-26
JP4800959B2 (ja)	2011-10-26
ES2373660T3 (es)	2012-02-07

Legal Events

Date	Code	Title	Description
2012-03-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
NO2010010I1 (no)	2010-06-07	Exendin-4 (Exenatid)
MXPA04003569A (es)	2004-07-23	Mezclas bifasicas de glp-1 e insulina.
AR022368A1 (es)	2002-09-04	Procedimiento para administrar peptidos insulinotropicos
WO2006029634A3 (en)	2006-09-08	Pharmaceutical compositions containing insulin and insulinotropic peptide
MXPA05007470A (es)	2005-09-21	Metodo para reducir la morbilidad y mortalidad cardiovascular en pacientes prediabeticos y pacientes con diabetes de tipo 2.
IL176541A0 (en)	2006-10-05	Intranasal administration of glucose-regulating peptides
CL2023000087A1 (es)	2023-07-07	Coagonistas de los receptores glp-1 y gip adecuados para el suministro oral
MX2023014771A (es)	2024-03-19	Conjugados peptidicos duales gip/glp-1 de accion prolongada y metodos de uso.
IL174154A (en)	2013-09-30	History of GLP-1 New Pharmaceutical Preparations Containing Them and Using It to Make Medicines
WO2006051110A3 (en)	2006-11-02	Stable formulations of insulinoptropic peptides
WO2006097536A3 (en)	2006-12-28	Dimeric peptide agonists of the glp-1 receptor
AU2003295614A8 (en)	2004-06-23	Delivery of pharmaceutical agents via the human insulin receptor
AR033903A1 (es)	2004-01-07	Una composicion de insulina modificada quimicamente para la administracion pulmonar
ATE541582T1 (de)	2012-02-15	Stabilisierte pharmazeutische glp-1 peptid zusammensetzungen
AU2003234529A8 (en)	2003-12-12	Glp-1 gene delivery for the treatment of type 2 diabetes
AR084558A1 (es)	2013-05-22	Metodos para tratar trastornos metabolicos y obesidad con peptidos basados en glucagon activos para el receptor de peptido insulinotropico dependiente de glucosa (gip)/peptido-1 similar al glucagon (glp-1)
AU2003217820A1 (en)	2003-09-16	Periocular drug delivery for diabetic retinopathy
CY1113755T1 (el)	2016-07-27	Η λιξισενατιδη ως επιπροσθετη αγωγη στην ινσουλινη γλαργινη και στη μετφορμινη για τη θεραπευτικη αντιμετωπιση του διαβητη τυπου 2
ATE354362T1 (de)	2007-03-15	Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff
CA3251240A1 (en)	2023-08-10	DUAL GLP-1 AND GLUCAGON AGONIST PEPTIDES WITH IMPROVED BIOLOGICAL STABILITY
Youn et al.	2008	Improved peroral delivery of glucagon-like peptide-1 by site-specific biotin modification: design, preparation, and biological evaluation
EA200702116A1 (ru)	2008-02-28	Фармацевтическая дозированная форма (варианты) с контролируемым высвобождением антигипергликемического средства в комбинации с производным тиазолидиндиона
MXPA05010613A (es)	2005-11-23	Formulacion parenteral de acido micofenolico, una sal o profarmaco del mismo.
PL1609481T3 (pl)	2008-02-29	Nadająca się do wstrzykiwania kompozycja farmaceutyczna zawierająca diklofenak sodowy, beta-cyklodekstrynę i polisorbat
WO2005041936A3 (en)	2005-08-04	Methods of treatment of cancer using a composition comprising a cytotoxic drug and a porous carrier material